Medical researchers at the University of Alberta have
discovered that combination drug therapy didn't work well in
clinical trials for cancer patients because one drug was making the
other drug ineffective.
New phase 3 data from the investigational therapy IDegLira
(insulin degludec [Tresiba®]/liraglutide injection [Victoza®]) were
presented at the World Diabetes Congress of the International
Patients suffering acetaminophen poisoning could be helped by
a small change in the way the antidote is delivered, say scientists
from the University of Edinburgh in the UK.The study, published in
The Lancet, shows that using the same antidote, acetylcysteine,
over a shorter time period leads to fewer side effects.
Almost half of parents said they'd allow their children to
take part if their child had the disease being studied, according
to U-M's National Poll on Children's Health To improve healthcare
for children, medical research that involves kids is a must.
AACC has released a position statement on harmonization of -
or ensuring uniformity among - clinical laboratory test results to
help patients receive appropriate diagnoses and medical treatment.
With this statement, the association aims to raise awareness about
this essential healthcare issue and urge the medical community to
work together to make harmonization a reality.
Topokine Therapeutics has initiated dosing in a Phase 2,
randomized controlled clinical trial of XAF5 Gel for reduction of
excess submental fat, commonly known as "double chin." XAF5 Gel is
a proprietary skin formulation of a compound already known to
reduce fat around the human eye. Study participants are applying
XAF5 Gel or placebo once a night to skin under the chin.
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has announced
that preclinical testing of a DNA synthetic vaccine for the
virulent Middle East Respiratory Syndrome coronavirus (MERS)
induced robust and durable immune responses, demonstrating the
potential for a SynCon® DNA vaccine to prevent and treat this
Merck (NYSE:MRK), known as MSD outside the United States and
Canada, today announced additional data for MK-3475, an
investigational anti-PD-1 immunotherapy, in patients with advanced
melanoma that showed an estimated overall survival rate of 81
percent at one year across all MK-3475 monotherapy doses